Application of wedelolactone in preparation of anti-pulmonary fibrosis drug

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.